EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Prognostic and Immunological Value of CTNNB1 in Pancreatic Adenocarcinoma: A Comprehensive NGS and Multicomponent Analysis

ShuYan Liu iD, Yichen Wu, Hong Zhou, Ying Ding iD

Genetics Research · 2026

DOI: 10.1155/genr/8700258 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Genetics Research, 2026. Verfasst von ShuYan Liu und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Nantong First People's Hospital, Nantong Jiangsu, 226001, China, nt2191.com. Hauptthemen laut MEDLINE: beta Catenin, Pancreatic Neoplasms, Biomarkers, Tumor, Carcinoma, Pancreatic Ductal. Die Arbeit nennt 92 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Nantong University Graduate Innovation Project, Nantong Social Livelihood Science and Technology Program of Jiangsu Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

To explore the prognostic value and immunomodulatory role of CTNNB1 in pancreatic ductal adenocarcinoma (PDAC), so as to provide evidence for the diagnosis and individualized treatment of PDAC.

Methods

Next‐generation sequencing (NGS) was performed to detect 425 cancer‐associated genes in PDAC specimens and matched normal pancreatic tissues. Integrative transcriptome analysis based on TCGA, GTEx, and multiple GEO datasets was conducted to identify the differential expression of CTNNB1 between PDAC and normal pancreatic tissues. The Human Protein Atlas (HPA, https://www.proteinatlas.org/ ) database was used to verify the protein expression and subcellular localization of CTNNB1 in normal pancreatic tissues and pancreatic ductal adenocarcinoma (PDAC) tissues. Single‐cell RNA‐sequencing and spatial transcriptomic data were further supplemented to delineate its cellular expression landscape. Forest plot, Kaplan–Meier survival analysis, and ROC curve analysis were applied to evaluate the correlations between CTNNB1 expression and prognostic and to verify its prognostic accuracy. The prognostic reliability was further validated using the independent cohort GSE57495. Immune cell infiltration and immune regulatory factors were quantified via TIMER, EPIC, MCPcounter, CIBERSORT, and xCell algorithms, and TMEscore was calculated to predict the responsiveness to immune checkpoint blockade (ICB). Pharmacogenomic datasets including GDSC1, GDSC2, PRISM, and CTRP were utilized to screen optimal candidate drugs for CTNNB1 ‐high PDAC patients.

Results

CTNNB1 was significantly overexpressed in PDAC compared with normal pancreatic tissues. HPA immunohistochemistry confirmed CTNNB1 shifts from membranous to cytoplasmic localization in PDAC, indicating activated Wnt signaling and concordant dysregulation at mRNA and protein levels. CTNNB1 protein was mainly localized in malignant epithelial cells of PDAC, with elevated expression also observed in partial immune cell subsets by single‐cell sequencing and spatial transcriptome assessment. Upregulated CTNNB1 was significantly linked to unfavorable clinical prognosis in PDAC. ROC analysis verified its good diagnostic efficiency for distinguishing PDAC from peritumoral tissues with favorable sensitivity and specificity. CTNNB1 expression was closely correlated with multiple immune biomarker molecules and ICB therapeutic efficacy; patients with low CTNNB1 expression tended to be more responsive to ICB treatment. Pharmacological prediction revealed that PDAC patients with high CTNNB1 expression exhibited enhanced sensitivity to clofibrate and several other small‐molecule compounds.

Conclusion

CTNNB1 may be remarkably effective as a suitable biomarker for the prognosis prediction of PDAC patients and is closely related to the tumor immune microenvironment. Such an association could provide novel thoughts for the therapy tactics and mechanistic studies toward PDAC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

beta CateninPancreatic NeoplasmsBiomarkers, TumorCarcinoma, Pancreatic DuctalAdenocarcinomaHumansPrognosisGene Expression Regulation, NeoplasticHigh-Throughput Nucleotide SequencingFemaleMaleTranscriptomeGene Expression Profiling

Stichwörter der Autor:innen

CTNNB1biomarkerimmune microenvironmentimmunotherapypancreatic cancerprognosis

Substanzen

beta CateninCTNNB1 protein, humanBiomarkers, Tumor

Autor:innen und Institutionen

  • Department of Pathology, Nantong First People's Hospital, Nantong Jiangsu, 226001, China, nt2191.com.
  • Department of Pharmaceutical Engineering, Nanjing University of Technology, Nanjing 210000, China, njtech.edu.cn.
  • Department of Pathology, The First Affiliated Hospital With Nanjing Medical University, Nanjing 210000, China, njmu.edu.cn.

ORCID-Profile: ShuYan Liu, Ying Ding

Förderung

  • National Natural Science Foundation of China
  • Nantong University Graduate Innovation Project
  • Nantong Social Livelihood Science and Technology Program of Jiangsu Province

Zitieren

APA

Liu, S., Wu, Y., Zhou, H., & Ding, Y. (2026). Prognostic and Immunological Value of CTNNB1 in Pancreatic Adenocarcinoma: A Comprehensive NGS and Multicomponent Analysis. Genetics Research. https://doi.org/10.1155/genr/8700258

Vancouver

Liu S, Wu Y, Zhou H, Ding Y. Prognostic and Immunological Value of CTNNB1 in Pancreatic Adenocarcinoma: A Comprehensive NGS and Multicomponent Analysis. Genetics Research. 2026. doi:10.1155/genr/8700258

BibTeX
@article{Liu2026,
  author = {Liu, ShuYan and Wu, Yichen and Zhou, Hong and Ding, Ying},
  title = {Prognostic and Immunological Value of CTNNB1 in Pancreatic Adenocarcinoma: A Comprehensive NGS and Multicomponent Analysis},
  journal = {Genetics Research},
  year = {2026},
  doi = {10.1155/genr/8700258}
}
Kostenlos starten →